47 results about "Glaucoma treatments" patented technology

A glaucoma treatment apparatus including an imaging device capable of imaging the anterior segment of the eye, a treatment laser, an algorithm programmed to determine a location and a cross sectional area of a treatment based on a customized anatomy of the anterior segment of the eye including the trabecular meshwork (TM), the Schlemm's Canal (SC) and collector channels (CCS), obtained from pre-operative images of the anterior segment of the eye, a pre-operative intraocular pressure (IOP) level and a target IOP reduction as an inputs, and a processor configured to actuate the apparatus to create an outflow channel with a cross-sectional area and location or multiple outflow channels with multiple cross-sectional areas and locations from the anterior chamber (AC) to the SC across the TM, as determined by the algorithm to achieve the target intraocular pressure (IOP) reduction. Also disclosed is a method of reducing intraocular pressure in an eye.

The invention relates generally to medical devices and methods for reducing the intraocular pressure in an animal eye and, more particularly, to stent type devices for permitting aqueous outflow from the eye's anterior chamber and associated methods thereof for the treatment of glaucoma. Some aspects provide a self-trephining glaucoma stent and methods thereof which advantageously allow for a “one-step” procedure in which the incision and placement of the stent are accomplished by a single device and operation. This desirably allows for a faster, safer, and less expensive surgical procedure.

A simulated eye surgical model with a bubble management system that facilitates training of ophthalmic surgical procedures, such as laser-based glaucoma treatment. The simulated eye could also be used for marketing, startup procedures, go / no-go tests, etc. The eye model has a lower core, a corneal dome positioned above the lower core, and an anterior chamber under the corneal dome defining a floor. A bubble reservoir under the anterior chamber defined by the lower core has a capture tube opening to the anterior chamber. A bubble chamber open to the capture tube rises up above the capture tube lower end to an upper portion sealed off from the anterior chamber. The eye model may be rotated 360° about a horizontal axis to transfer bubbles from the anterior chamber to the bubble chamber. An alternative flow-through eye model provides active flushing of bubbles and particulate.

The invention discloses an implanted micropump driving system and method for glaucoma treatment, and relates to the field of driving systems.The driving system comprises a receiving coil, a power management module, a microprocessor control module and a driving module, the receiving coil is connected with the power management module, and the microprocessor control module is connected with the driving module; the power supply management module is respectively connected with the microprocessor control module and the driving module, and the microprocessor control module is connected with the driving module; the driving method comprises the following steps that the receiving coil receives energy of the transmitting coil, the power management module converts the energy into a stable power supply voltage signal and transmits the power supply voltage signal to the microprocessor control module and the driving module, and the microprocessor control module generates an analog signal and a control signal; the driving module processes the analog signal and the control signal, outputs a high-voltage square wave signal, and drives the piezoelectric micropump through the high-voltage square wave signal; secondary injury to the patient is reduced, the micropump is accurately controlled, and the intraocular pressure of the glaucoma patient is effectively reduced.

The invention relates to the technical field of biology. Specifically, the invention relates to an enhancer and a promoter for eye gene therapy, and a recombinant adeno-associated virus vector containing the enhancer and the promoter. The invention also relates to a pharmaceutical composition comprising the recombinant adeno-associated virus vector and its use in the treatment of glaucoma.

Methods for treating open-angle glaucoma include transitioning a patient from a twice-per-day or more treatment regimen to a once-per-day treatment regimen. The once-per-day treatment include administering a single dose of a pharmaceutical composition including timolol or a pharmaceutically acceptable salt thereof, brimonidine or a pharmaceutically acceptable salt thereof, dorzolamide or a pharmaceutically acceptable salt thereof, and bimatoprost or a pharmaceutically acceptable salt thereof, once per day.

A system includes a first light source configured to emit visible light according to one or more first parameters and a second light source configured to emit treatment light for altering patient tissue. A surgical instrument includes a distal portion configured to insert within an eye of a patient and an optical fiber conducts light from the first and second light sources to a tip of the distal portion. One or more sensors are configured to detect a state of the tip of the distal portion relative to the patient tissue. A controller is coupled to the one or more sensors, the first light source, and the second light source. The controller is configured to select values for the one or more first parameters according to the state of the tip of the distal portion relative to the patient tissue.

To provide a composition for lowering an eye pressure in a glaucoma patient.SOLUTION: In one aspect, the present disclosure provides a composition for lowering an eye pressure in a glaucoma patient, containing brimonidine or its pharmaceutically acceptable salt and timolol or its pharmaceutically acceptable salt. The composition of the present disclosure targets a patient of glaucoma. The composition of the present disclosure may be administered to a patient who has been treated with other glaucoma therapeutics but has not shown sufficient treatment effect.SELECTED DRAWING: None

Disclosed is a glaucoma device (10, 1010) comprising: an implant body (15, 1015) including an anterior portion (20, 1020), a distal portion (35, 1035), a plurality of arms (40, 1040) extending between the anterior portion (20, 1020) and the distal portion (35, 1035) to provide connection therebetween; and a fluid network extending from the anterior portion (20, 1020) along at least one of the arms (40, 1040) to the distal portion (35, 1035), the fluid network providing a plurality of outlet channels (90, 1090) for fluid exit therefrom; and a fluid inlet cannula (30, 1030) arranged on the anterior portion (20, 1020) of the implant body (15, 1015) and adapted for fluid connection with ocular tissue.

The utility model relates to the field of eye-protection lamps, in particular to an eye-protection lamp for preventing glaucoma, which comprises a mounting mechanism and a lamp holder, the PCB connecting plate is arranged at the bottom of the mounting mechanism, a lower light source is arranged at the bottom of the PCB connecting plate, and light emitted by the lower light source is infrared light with the wave band of 830 nm; the inner peripheral wall of the lampshade is connected with the PCB connecting plate, and the lampshade is located on the outer side of the outer peripheral face of the lower light source. According to the utility model, the power supply of the PCB connecting plate is switched on, and the PCB connecting plate is controlled to work through the switch, so that the lower light source and the upper light source can emit infrared light with the wave band of 830nm, the light therapy is realized, the glaucoma is prevented, the treatment equipment is an eye-protection lamp, and the eye-protection lamp is simple in structure and convenient to popularize for the broad masses to use.

The invention relates to a drug sustained release system, in particular to lipid liquid crystal precursor eye drops as well as a preparation method and application thereof. The lipid liquid crystal precursor eye drops comprise a matrix material, a cosolvent and a raw material medicine, wherein the matrix material is an amphiphilic substance and an oil phase; the lipid liquid crystal precursor eye drops are prepared from the following components in percentage by weight: 0 to 35 percent of amphiphilic substance, 40 to 80 percent of oil phase, 15 to 20 percent of cosolvent and 0.001 to 5 percent of raw material medicine. According to the constructed drug-loaded lipid liquid crystal precursor eye drops, when the drug-loaded lipid liquid crystal precursor makes contact with water in tears, the drug-loaded lipid liquid crystal precursor can instantly become drug-loaded lipid liquid crystal gel, compared with common eye drops, the retention time of the drug-loaded lipid liquid crystal gel on the ocular surface is longer, the lipid liquid crystal has a phospholipid bilayer structure, and the drug-loaded lipid liquid crystal gel can be used for preparing the drug-loaded lipid liquid crystal precursor eye drops. Insoluble raw material medicines can be distributed in the lipid layer, so that the solubility of the raw material medicines is greatly improved, the raw material medicines can be slowly released by gelatinizing after meeting water, the administration frequency is reduced, the bioavailability and patient compliance are greatly improved, and the defects of the eye drops in treatment of glaucoma are overcome.

This invention relates to an ophthalmic method and apparatus for the treatment of glaucoma. It provides an apparatus and method of illuminating a microcatheter tip either by using green light for optimised visualisation, blue light to stimulate fluorescence or IR light in conjunction with a dye for angiography of vascular structures the light produced by an LED coupled to an optical fibre. Laser focussing optics is used and back scatter through the fibre is monitored. The backscatter information is used to automatically signify priming of the microcatheter with a fluid or signal changes in a fluid pump function or multiple fluid deliveries through a single microcatheter. Furthermore, the backscatter information offers the potential for automatic dispensation of fluids with or without operator intervention.

The utility model provides an ultrasonic fusion probe and glaucoma treatment equipment, and relates to the technical field of ophthalmology medical instruments, the ultrasonic fusion probe provided by the utility model comprises an ultrasonic imaging probe, a focused ultrasonic treatment probe and a rotating frame; the ultrasonic imaging probe is mounted on the rotating frame; and the focused ultrasonic treatment probe is detachably connected with the rotating frame. According to the ultrasonic fusion probe, synchronous action control of the ultrasonic imaging probe and the focused ultrasonic treatment probe can be achieved, the control difficulty is reduced, the focused ultrasonic treatment probe can be replaced according to needs, and the ultrasonic fusion probe is particularly suitable for accurate and quantitative treatment of glaucoma.

Systems and devices for applying radiation to a target area, for example for maintaining functioning drainage blebs or functioning drainage holes in the eye, e.g., to reduce intraocular pressure (IOP) of an eye being treated for glaucoma. The systems and devices of the present invention provide for the application of beta radiation to the target area, wherein the beta radiation can function to inhibit or reduce the inflammation and / or fibrogenesis that may occur after insertion of an implant into the eye or introduction of a hole for the purpose of draining aqueous humor to maintain a healthy intraocular pressure. By reducing inflammation and / or fibrogenesis, the implant, the hole, the blebs, or other related structures or tissues can remain functioning appropriately.

The invention relates to a method and device for treating eye diseases, and belongs to the field of medical treatment. In order to treat ocular hypertension and glaucoma, a device for reducing intraocular pressure is provided, the device comprising: a plate having a first end and a second end, the plate comprising opposing first and second surfaces wherein the first surface comprises a series of fluid channels, the series of fluid channels are configured in an open cross-network pattern extending from a first end of the plate to a second end of the plate, the width of the first end of the plate being narrower than the width of the second end of the plate to enable the first end of the plate to be inserted into the anterior chamber of the patient, and wherein the second surface comprises a plurality of open cells formed by the fluid channels; a first coating on the first surface, the first coating conforming to a topography of the series of fluid channels, and a second coating on the second surface. The devices described herein can be used to reduce intraocular pressure and treat glaucoma.

The present technology is directed to implantable medical devices for draining fluid from a first body region to a second body region. Some embodiments of the present technology provide adjustable devices that are selectively titratable to provide various levels of therapy. For example, the adjustable devices can have a drainage element with a lumen extending therethrough, a flow control element, and an actuation assembly. The actuation assembly can drive movement of the flow control element to change a dimension of and / or a flow resistance through the lumen, thereby increasing or decreasing the relative drainage rate of aqueous from an eye. In some embodiments, the actuation assembly and the flow control element together operate as a ratchet mechanism that can selectively move the flow control element between a plurality of positions and lock the device in a desired configuration until further actuation of the actuation assembly.

Methods, systems, and compositions for maintaining functional drainage blisters to reduce intraocular pressure (IOP) for treatment with glaucoma. The methods, systems, and compositions are characterized by minimally invasive glaucoma surgery (MIGS) implants or surgery in combination with application of beta rays to bubbles. The beta-rays may act to inhibit or reduce inflammation and / or fibrosis that typically occurs after insertion of the MIGS implant and results in blister failure. By reducing inflammation and / or fibrosis, the MIGS implants and vesicles may maintain appropriate function.

The invention belongs to the field of nano material synthesis, and particularly relates to a core-shell structure piezoelectric composite material loaded NO donor nano particle and application thereof.The core-shell structure piezoelectric composite material loaded NO donor nano particle comprises a core and a shell layer, the core is made of a layered bismuth-based piezoelectric material, the shell layer is made of a porous material, and the shell layer is made of a porous material. The nanoparticles with the core-shell structure are loaded with an NO donor drug. The nano-drug delivery system can be used as an eye drug delivery system based on ultrasonic mediation, and the first low-frequency ultrasonic response type nano-drug is provided for glaucoma treatment. By means of the innovative design of piezoelectric core / MOF drug loading / PDA sealing / PEG functionalization, the three problems that in glaucoma treatment, drug targeting is poor, release is uncontrollable, and frequent drug administration is needed are solved, and a safe, efficient and micro-intervention nanometer treatment new normal form is provided for irreversible blinding diseases.

An improved stimulus coil for use in wireless stimulation of biological tissue (e.g., nerves, muscle tissue, etc.) and, in one exemplary implementation, to glaucoma therapy based on the wireless administration of energy to the eye of a mammalian subject (e.g., human, rodent, etc.) to reduce an elevated intraocular pressure (IOP) involving the use of an improved stimulus coil. The improved stimulus coil may be implanted in the eye of a mammalian subject or positioned on the exterior of the eye, such as (by way of example) by being disposed within a contact lens worn by a mammalian subject.

The handheld fiber probe (2) is used for laser treatment of medical tissue, in particular for glaucoma treatment. At least in the assembled state, it comprises an optical fiber cable (8). The fiber probe (2) has a housing (10) with a front end (18) providing an exit point for laser light. The fiber probe (2) has a front and a rear lens (16A, 16B), which can be adjusted relative to one another by the user, so that the focus of the laser beam can be varied by varying a distance (A) between the two lenses (16A, 16B).

The invention discloses an application of a miR-27a-3p inhibitor in preparation of a medicine for improving glaucoma. Glaucoma is a global main blinding neurodegenerative disease, retinal ganglion cell (RGC) apoptosis is a core pathological feature of the glaucoma, and existing intraocular pressure reduction treatment still cannot completely prevent neurodegenerative progress. Experiments prove that the miR-27a-3p inhibitor can be combined with 3 'UTR of PLK2 in a targeted mode, expression of the PLK2 is up-regulated, a PI3K / AKT signal channel is activated, and therefore RGC apoptosis is inhibited. A new glaucoma treatment strategy is provided, and the miR-27a-3p inhibitor can serve as an effective medicine to be used for improving glaucoma symptoms, protecting RGC and delaying disease progression and has good application prospects.

An ocular electrolysis device is described that may include a diverting tube configured for insertion into an eye. The ocular electrolysis device may include an electrolysis chamber mechanically attached to the diverting tube such that aqueous humor from the eye enters the electrolysis chamber through the diverting tube. The ocular electrolysis device may include a pressure sensor located in the electrolysis chamber. The ocular electrolysis device may include a pair of electrodes located in the electrolysis chamber. The ocular electrolysis device may include a controller electrically connected to the pair of the electrodes and the pressure sensor, where the controller regulates electrolysis of the aqueous humor in the electrolysis chamber based on input from the pressure sensor through power levels at the pair of electrodes. Monitored reduction of aqueous humor by electrolysis regulates the control of intraocular pressure.

The present technology is directed to implantable medical devices for draining fluid from a first body region to a second body region. Some embodiments of the present technology provide adjustable devices that are selectively titratable to provide various levels of therapy. For example, the adjustable devices can have a drainage element with a lumen extending therethrough, a flow control element, and an actuation assembly. The actuation assembly can drive movement of the flow control element to change a dimension of and / or a flow resistance through the lumen, thereby increasing or decreasing the relative drainage rate of aqueous from an eye. In some embodiments, the actuation assembly and the flow control element together operate as a ratchet mechanism that can selectively move the flow control element between a plurality of positions and lock the device in a desired configuration until further actuation of the actuation assembly.

This invention discloses a glaucoma aqueous humor drainage tube implantation and injection device, relating to the field of glaucoma treatment technology. It includes a shell, with a baffle one and a baffle two fixedly connected to the inner wall of the shell. A cylinder is fixedly connected to the inner wall of baffle one and the top surface of baffle two. A drainage component is disposed inside the cylinder, and two sealing blocks are disposed below the cylinder. Body parts are fixedly connected to both sides of the shell, and adhesive patches are disposed below the two body parts. A driving component is disposed inside the shell. It also includes two sets of eye-expanding components, each disposed within one of the two body parts. The two sets of eye-expanding components allow the two adhesive patches to move synchronously with angular trajectory characteristics. Furthermore, it includes two sets of protective components, which allow the two sealing blocks to move in opposite directions. Through the cooperation of the above structures, this invention assists doctors in treating patients and helps patients recover better.

A glaucoma drainage device is provided having an elongated body for draining aqueous humor from the anterior chamber of the eye. At least one anchor or wire is configured to extend radially outward beyond the body to secure the body within the eye. The device, including the anchor or wire, is housed within the distal end of a needle inserter and deployed from there to implant the device within the eye. Deployment is performed by an extraocular or intraocular method. Once the device is loaded inside the needle inserter, the wire or anchor (or part thereof) is held in a compressed state. The wire or anchor (or part thereof) is configured to automatically expand from the compressed state to secure the device within the eye once deployed into the eye from the needle inserter. Related systems and methods for treating glaucoma are also described and claimed.

To provide adjustable glaucoma treatment devices, and associated systems and methods.SOLUTION: The present technology is directed to implantable medical devices for draining fluid from a first body region to a second body region. Some embodiments of the present technology provide adjustable devices that are selectively titratable to provide various levels of therapy. For example, the adjustable devices can have a drainage element with a lumen extending therethrough, a flow control element, and an actuation assembly. The actuation assembly can drive movement of the flow control element to change a dimension of and / or a flow resistance through the lumen, thereby increasing or decreasing the relative drainage rate of aqueous humor from an eye. In some embodiments, the actuation assembly and the flow control element together operate as a ratchet mechanism that can selectively move the flow control element between a plurality of positions and lock the device in a desired configuration until further actuation of the actuation assembly.SELECTED DRAWING: Figure 2

Glaucoma treatment systems are disclosed. In various example, the glaucoma treatment systems include a body and a fluid conduit configured to facilitate an evacuation of fluid, such as aqueous humor, from a fluid-filled body cavity, such as an anterior chamber of an eye. In some examples, the fluid conduit is soft and compliant, and the glaucoma treatment system includes one or more stiffening members coupled with the fluid conduit to temporarily stiffen the fluid conduit and help aid in the delivery of the glaucoma treatment device. In some examples, the stiffening members are removable from the fluid conduit after the glaucoma treatment system has been implanted.

A simulated eye surgical model with a bubble management system that facilitates training of ophthalmic surgical procedures, such as laser-based glaucoma treatment. The simulated eye could also be used for marketing, startup procedures, go / no-go tests, etc. The eye model has a lower core, a corneal dome positioned above the lower core, and an anterior chamber under the corneal dome defining a floor. A bubble reservoir under the anterior chamber defined by the lower core has a capture tube opening to the anterior chamber. A bubble chamber open to the capture tube rises up above the capture tube lower end to an upper portion sealed off from the anterior chamber. The eye model may be rotated 360° about a horizontal axis to transfer bubbles from the anterior chamber to the bubble chamber. An alternative flow-through eye model provides active flushing of bubbles and particulate.

An improved stimulus coil for use in wireless stimulation of biological tissue (e.g., nerves, muscle tissue, etc.) and, in one exemplary implementation, to glaucoma therapy based on the wireless administration of energy to the eye of a mammalian subject (e.g., human, rodent, etc.) to reduce an elevated intraocular pressure (IOP) involving the use of an improved stimulus coil. The improved stimulus coil may be implanted in the eye of a mammalian subject or positioned on the exterior of the eye, such as (by way of example) by being disposed within a contact lens worn by a mammalian subject.